Barrier or carrier? Pulmonary surfactant and drug delivery

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 95, Issue , 2015, Pages 117-127

  Hidalgo, Alberto ^a   Cruz, Antonio ^a   Pérez Gil, Jesús ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Air liquid interface; Inhalation; Lung surfactant; Monolayer; Nanocarriers; Nanoparticles; Respiratory nanomedicine

Indexed keywords

ADENOVIRUS VECTOR; ARTIFICIAL LUNG SURFACTANT; DENDRIMER; LIPOSOME; LUNG SURFACTANT; NANOCARRIER; SOLID LIPID NANOPARTICLE; DRUG CARRIER;

AIR; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HISTORY OF MEDICINE; HUMAN; INHALATION; LIQUID; MICELLE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERIZATION; TARGET ORGAN; ANIMAL; CHEMICAL PHENOMENA; CYTOLOGY; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; PROCEDURES; SURFACE TENSION;

ADMINISTRATION, INHALATION; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LUNG; PULMONARY SURFACTANTS; SURFACE TENSION;

EID: 84944277448     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.02.014     Document Type: Article

References (113)

1. F. Kesisoglou, and Y. Wu Understanding the effect of API properties on bioavailability through absorption modeling AAPS J. 10 4 2008 516 525
2. B.K. Rubin, and R.W. Williams Emerging aerosol drug delivery strategies: from bench to clinic Adv. Drug Deliv. Rev. 2014
3. F. Ungaro, I. d'Angelo, A. Miro, M.I. La Rotonda, and F. Quaglia Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises J. Pharm. Pharmacol. 64 9 2012 1217 1235
4. C. Loira-Pastoriza, J. Todoroff, and R. Vanbever Delivery strategies for sustained drug release in the lungs Adv. Drug Deliv. Rev. 75c 2014 81 91
5. B. Olsson, E. Bondesson, L. Borgström, S. Edsbäcker, S. Eirefelt, K. Ekelund, and et al. Pulmonary drug metabolism, clearance, and absorption Controlled Pulmonary Drug Delivery 2011 Springer 21 50
6. S. Weber, A. Zimmer, and J. Pardeike Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art Eur. J. Pharm. Biopharm.: Off. J. Arbeitsgemeinsc. Pharm. Verfahrenstechnik eV 86 1 2014 7 22
7. C. de Souza Carvalho, N. Daum, and C.M. Lehr Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery Adv. Drug Deliv. Rev. 75c 2014 129 140
8. P. Dietl, and T. Haller Exocytosis of lung surfactant: from the secretory vesicle to the air-liquid interface Annu. Rev. Physiol. 67 2005 595 621
9. R. Subbiah, M. Veerapandian, and K.S. Yun Nanoparticles: functionalization and multifunctional applications in biomedical sciences Curr. Med. Chem. 17 36 2010 4559 4577
10. H.L. Halliday Surfactants: past, present and future J. Perinatol.: Off. J. Calif. Perin. Assoc. 28 Suppl. 1 2008 S47 S56
11. E. Lopez-Rodriguez, and J. Perez-Gil Structure-function relationships in pulmonary surfactant membranes: from biophysics to therapy Biochim. Biophys. Acta 1838 6 2014 1568 1585
12. J.J. Haitsma, U. Lachmann, and B. Lachmann Exogenous surfactant as a drug delivery agent Adv. Drug Deliv. Rev. 47 2-3 2001 197 207
13. C. Vermehren, S. Frokjaer, T. Aurstad, and J. Hansen Lung surfactant as a drug delivery system Int. J. Pharm. 307 1 2006 89 92
14. E. Parra, A. Alcaraz, A. Cruz, V.M. Aguilella, and J. Perez-Gil Hydrophobic pulmonary surfactant proteins SP-B and SP-C induce pore formation in planar lipid membranes: evidence for proteolipid pores Biophys. J. 104 1 2013 146 155
15. E. Parra, L.H. Moleiro, I. Lopez-Montero, A. Cruz, F. Monroy, and J. Perez-Gil A combined action of pulmonary surfactant proteins SP-B and SP-C modulates permeability and dynamics of phospholipid membranes Biochem. J. 438 3 2011 555 564
16. J. Perez-Gil, and T.E. Weaver Pulmonary surfactant pathophysiology: current models and open questions Physiology 25 3 2010 132 141
17. J. Goerke Pulmonary surfactant: functions and molecular composition Biochim. Biophys. Acta 1408 2-3 1998 79 89
18. S.A. Shelley, J.E. Paciga, and J.U. Balis Lung surfactant phospholipids in different animal species Lipids 19 11 1984 857 862
19. S. Orgeig, P.S. Hiemstra, E.J. Veldhuizen, C. Casals, H.W. Clark, A. Haczku, and et al. Recent advances in alveolar biology: evolution and function of alveolar proteins Respir. Physiol. Neurobiol. 173 2010 S43 S54
20. S. Orgeig, W. Bernhard, S.C. Biswas, C.B. Daniels, S.B. Hall, S.K. Hetz, and et al. The anatomy, physics, and physiology of gas exchange surfaces: is there a universal function for pulmonary surfactant in animal respiratory structures? Integr. Comp. Biol. 47 4 2007 610 627
21. L.N.M. Suri, A. Cruz, R.A.W. Veldhuizen, J.F. Staples, F. Possmayer, S. Orgeig, and et al. Adaptations to hibernation in lung surfactant composition of 13-lined ground squirrels influence surfactant lipid phase segregation properties Biochim. Biophys. Acta (BBA) - Biomembr. 1828 8 2013 1707 1714
22. R. Veldhuizen, K. Nag, S. Orgeig, and F. Possmayer The role of lipids in pulmonary surfactant Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1408 2 1998 90 108
23. K.A. Brogden Changes in pulmonary surfactant during bacterial pneumonia Antonie Van Leeuwenhoek 59 4 1991 215 223
24. O. Blanco, and J. Perez-Gil Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: role of the different components in an efficient pulmonary surfactant Eur. J. Pharmacol. 568 1-3 2007 1 15
25. J. Perez-Gil Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions Biochim. Biophys. Acta 1778 7-8 2008 1676 1695
26. 2 diffusion through the air-water interface Biochim. Biophys. Acta (BBA) - Biomembr. 1798 6 2010 1281 1284
27. M. Griese Pulmonary surfactant in health and human lung diseases: state of the art Eur. Respir. J. 13 6 1999 1455 1476
28. S.E. Wert, J.A. Whitsett, and L.M. Nogee Genetic disorders of surfactant dysfunction Pediat. Develop. Pathol.: Off. J. Soc. Pediat. Pathol. Paediat. Pathol. Soc. 12 4 2009 253 274
29. E. Lopez-Rodriguez, M. Echaide, A. Cruz, H.W. Taeusch, and J. Perez-Gil Meconium impairs pulmonary surfactant by a combined action of cholesterol and bile acids Biophys. J. 100 3 2011 646 655
30. R.A. Polin, W.A. Carlo, L.-A. Papile, W. Carlo, R. Tan, P. Kumar, and et al. Surfactant replacement therapy for preterm and term neonates with respiratory distress Pediatrics 133 1 2014 156 163
31. M.E. Avery, and J. Mead Surface properties in relation to atelectasis and hyaline membrane disease AMA J. Dis. Child. 97 5, Part 1 1959 517 523
32. T. Curstedt, and J. Johansson Different effects of surfactant proteins B and C - implications for development of synthetic surfactants Neonatology 97 4 2010 367 372
33. G. Enhorning, and B. Robertson Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant Pediatrics 50 1 1972 58 66
34. G. Enhorning, G. Grossmann, and B. Robertson Pharyngeal deposition of surfactant in the premature rabbit fetus Biol. Neonate 22 1 1973 126 132
35. F.H. Adams, B. Towers, A.B. Osher, M. Ikegami, T. Fujiwara, and M. Nozaki Effects of tracheal instillation of natural surfactant in premature lambs. I. Clinical and autopsy findings Pediatr. Res. 12 8 1978 841 848
36. T. Fujiwara, H. Maeta, S. Chida, T. Morita, Y. Watabe, and T. Abe Artificial surfactant therapy in hyaline-membrane disease Lancet 1 8159 1980 55 59
37. H.L. Halliday Overview of clinical trials comparing natural and synthetic surfactants Biol. Neonate 67 Suppl. 1 1995 32 47
38. T. Curstedt, and J. Johansson New synthetic surfactant - how and when? Neonatology 89 4 2006 336 339
39. C.G. Cochrane, S.D. Revak, T.A. Merritt, G.P. Heldt, M. Hallman, M.D. Cunningham, and et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome Am. J. Respir. Crit. Care Med. 153 1 1996 404 410
40. R.G. Spragg, J.F. Lewis, W. Wurst, D. Hafner, R.P. Baughman, M.D. Wewers, and et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant Am. J. Respir. Crit. Care Med. 167 11 2003 1562 1566
41. M. Seehase, J.J. Collins, E. Kuypers, R.K. Jellema, D.R. Ophelders, O.L. Ospina, and et al. New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs PLoS ONE 7 10 2012 e47631
42. Veen. Avt, J.W. Mouton, D. Gommers, and B. Lachmann Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae Br. J. Pharmacol. 119 6 1996 1145 1148
43. A. Van't Veen, D. Gommers, S.J. Verbrugge, P. Wollmer, J.W. Mouton, P.P. Kooij, and et al. Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle Br. J. Pharmacol. 126 5 1999 1091 1096
44. E. Herting, X. Gan, P. Rauprich, C. Jarstrand, and B. Robertson Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia Am. J. Respir. Crit. Care Med. 159 6 1999 1862 1867
45. M. Liu, L. Wang, E. Li, and G. Enhorning Pulmonary surfactant given prophylactically alleviates an asthma attack in guinea-pigs Clin. Exp. Allergy 26 3 1996 270 275
46. J.P. Katkin, R.C. Husser, C. Langston, and S.E. Welty Exogenous surfactant enhances the delivery of recombinant adenoviral vectors to the lung Hum. Gene Ther. 8 2 1997 171 176
47. F.J. Walther, R. David-Cu, and S.L. Lopez Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits Am. J. Physiol. - Lung Cell. Mol. Physiol. 13 5 1995 L613
48. J. Mazela, T.A. Merritt, J. Gadzinowski, and S. Sinha Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases Acta Paediatr. (Oslo, Norway: 1992) 95 9 2006 1036 1048
49. D. Mokra, J. Mokry, A. Drgova, M. Petraskova, J. Bulikova, and A. Calkovska Intratracheally administered corticosteroids improve lung function in meconium-instilled rabbits J. Physiol. Pharmacol.: Off. J. Polish Physiol. Soc. 58 Suppl. 5(Pt 1) 2007 389 398
50. P. Mikolka, D. Mokra, J. Kopincova, L. Tomcikova-Mikusiakova, and A. Calkovska Budesonide added to modified porcine surfactant Curosurf may additionally improve the lung functions in meconium aspiration syndrome Physiol. Res./Acad. Sci. Bohemoslov. 62 Suppl. 1 2013 S191 S200
51. C. Dani, I. Corsini, S. Burchielli, V. Cangiamila, M. Longini, F. Paternostro, and et al. Natural surfactant combined with beclomethasone decreases oxidative lung injury in the preterm lamb Pediatr. Pulmonol. 44 12 2009 1159 1167
52. C. Dani, I. Corsini, S. Burchielli, V. Cangiamila, R. Romagnoli, B. Jayonta, and et al. Natural surfactant combined with beclomethasone decreases lung inflammation in the preterm lamb Respirat.: Int. Rev. Thoracic Dis. 82 4 2011 369 376
53. G. Chimote, and R. Banerjee Effect of antitubercular drugs on dipalmitoylphosphatidylcholine monolayers: implications for drug loaded surfactants Respir. Physiol. Neurobiol. 145 1 2005 65 77
54. M. Kolomaznik, A. Calkovska, E. Herting, and G. Stichtenoth Biophysical activity of animal-derived exogenous surfactants mixed with rifampicin Adv. Exp. Med. Biol. 2014
55. A. Birkun Exogenous pulmonary surfactant as a vehicle for antimicrobials: assessment of surfactant-antibacterial interactions in vitro Scientifica 2014 2014 930318
56. E. Berggren, M. Liljedahl, B. Winbladh, B. Andreasson, T. Curstedt, B. Robertson, and et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome Acta Paediatr. (Oslo, Norway: 1992) 89 4 2000 460 464
57. F.J. Walther, J.M. Hernández-Juviel, and A.J. Waring Aerosol delivery of synthetic lung surfactant PeerJ. 2 2014 e403
58. C. Morley, N. Miller, A. Bangham, and J. Davis Dry artificial lung surfactant and its effect on very premature babies The Lancet 317 8211 1981 64 68
59. A. Wilkinson, P. Jenkins, and J. Jeffrey Two controlled trials of dry artificial surfactant: early effects and later outcome in babies with surfactant deficiency The Lancet 326 8450 1985 287 291
60. Q.T. Zhou, P. Tang, S.S.Y. Leung, J.G.Y. Chan, and H.-K. Chan Emerging inhalation aerosol devices and strategies: where are we headed? Adv. Drug Deliv. Rev. 2014
61. H.-I. Chang, and M.-K. Yeh Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy Int. J. Nanomed. 7 2012 49
62. M.L. Tan, P.F. Choong, and C.R. Dass Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery Peptides 31 1 2010 184 193
63. W. Xu, P. Ling, and T. Zhang Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs J. Drug Deliv. 2013
64. J.C. Sung, B.L. Pulliam, and D.A. Edwards Nanoparticles for drug delivery to the lungs Trends Biotechnol. 25 12 2007 563 570
65. C. Jud, M.J. Clift, A. Petri-Fink, and B. Rothen-Rutishauser Nanomaterials and the human lung: what is known and what must be deciphered to realise their potential advantages? Swiss Med. Week. 143 2013 w13758
66. J.C. Sung, D.J. Padilla, L. Garcia-Contreras, J.L. Verberkmoes, D. Durbin, C.A. Peloquin, and et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery Pharm. Res. 26 8 2009 1847 1855
67. D.J. Bharali, V. Pradhan, G. Elkin, W. Qi, A. Hutson, S.A. Mousa, and et al. Novel nanoparticles for the delivery of recombinant hepatitis B vaccine Nanomed. Nanotechnol. Biol. Med. 4 4 2008 311 317
68. X. Yuan, L. Li, A. Rathinavelu, J. Hao, M. Narasimhan, M. He, and et al. SiRNA drug delivery by biodegradable polymeric nanoparticles J. Nanosci. Nanotechnol. 6 9-10 2006 2821 2828
69. O.M. Merkel, I. Rubinstein, and T. Kissel SiRNA delivery to the lung: what's new? Adv. Drug Deliv. Rev. 75c 2014 112 128
70. Y. Kawashima, H. Yamamoto, H. Takeuchi, S. Fujioka, and T. Hino Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect J. Control. Release: Off. J. Control. Release Soc. 62 1-2 1999 279 287
71. F. Ungaro, R. d'Emmanuele di Villa Bianca, C. Giovino, A. Miro, R. Sorrentino, F. Quaglia, and et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs J. Control. Release: Off. J. Control. Release Soc. 135 1 2009 25 34
72. Y.J. Oh, J. Lee, J.Y. Seo, T. Rhim, S.H. Kim, H.J. Yoon, and et al. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model J. Control. Release: Off. J. Control. Release Soc. 150 1 2011 56 62
73. T.V.P. Doan, N. Grégoire, I. Lamarche, P. Gobin, S. Marchand, W. Couet, and et al. A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin Eur. J. Pharm. Sci. 48 1-2 2013 223 230
74. J. Lee, Y.J. Oh, S.K. Lee, and K.Y. Lee Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery J. Control. Release 146 1 2010 61 67
75. C. Lee, J.S. Choi, I. Kim, K.T. Oh, E.S. Lee, E.S. Park, and et al. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes Int. J. Nanomed. 8 2013 2975 2983
76. S. Mignani, S. El Kazzouli, M. Bousmina, and J.-P. Majoral Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview Adv. Drug Deliv. Rev. 65 10 2013 1316 1330
77. Y. Cheng, Z. Xu, M. Ma, and T. Xu Dendrimers as drug carriers: applications in different routes of drug administration J. Pharm. Sci. 97 1 2008 123 143
78. L.M. Kaminskas, V.M. McLeod, G.M. Ryan, B.D. Kelly, J.M. Haynes, M. Williamson, and et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy J. Control. Release 183 2014 18 26
79. M. Nasr, M. Najlah, A. D'Emanuele, and A. Elhissi PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization Int. J. Pharm. 461 1-2 2014 242 250
80. R. Inapagolla, B.R. Guru, Y.E. Kurtoglu, X. Gao, M. Lieh-Lai, D.J.P. Bassett, and et al. In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation Int. J. Pharm. 399 1-2 2010 140 147
81. S.R. Croy, and G.S. Kwon Polymeric micelles for drug delivery Curr. Pharm. Des. 12 36 2006 4669 4684
82. Z. Ahmad, A. Shah, M. Siddiq, and H.-B. Kraatz Polymeric micelles as drug delivery vehicles RSC Adv. 4 33 2014 17028 17038
83. M.N. Sahib, Y. Darwis, K.K. Peh, S.A. Abdulameer, and Y.T. Fung Tan Incorporation of beclomethasone dipropionate into polyethylene glycol-diacyl lipid micelles as a pulmonary delivery system Drug Develop. Res. 73 2 2012 90 105
84. A.D. Bangham, M.M. Standish, and J.C. Watkins Diffusion of univalent ions across the lamellae of swollen phospholipids J. Mol. Biol. 13 1 1965 238 252
85. Y. Perrie Gregory Gregoriadis: introducing liposomes to drug delivery J. Drug Target. 16 7-8 2008 518 519
86. T.M. Allen, and P.R. Cullis Liposomal drug delivery systems: from concept to clinical applications Adv. Drug Deliv. Rev. 65 1 2013 36 48
87. G. Bonacucina, M. Cespi, M. Misici-Falzi, and G.F. Palmieri Colloidal soft matter as drug delivery system J. Pharm. Sci. 98 1 2009 1 42
88. M. Beck-Broichsitter, M. Rieger, R. Reul, T. Gessler, W. Seeger, and T. Schmehl Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations Eur. J. Pharm. Biopharm. 84 1 2013 106 114
89. D. Cipolla, B. Shekunov, J. Blanchard, and A. Hickey Lipid-based carriers for pulmonary products: preclinical development and case studies in humans Adv. Drug Deliv. Rev. 2014
90. L. Willis, D. Hayes Jr., and H.M. Mansour Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery Lung 190 3 2012 251 262
91. J. Pardeike, A. Hommoss, and R.H. Muller Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products Int. J. Pharm. 366 1-2 2009 170 184
92. W. Yang, J.I. Peters, and R.O. Williams Iii Inhaled nanoparticles - a current review Int. J. Pharm. 356 1-2 2008 239 247
93. P.A. Jaques, and C.S. Kim Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women Inhalation Toxicol. 12 8 2000 715 731
94. A.H. de Boer, D. Gjaltema, P. Hagedoorn, and H.W. Frijlink Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique Int. J. Pharm. 249 1-2 2002 219 231
95. P.R. Byron Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation J. Pharm. Sci. 75 5 1986 433 438
96. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 1-2 2010 1 19
97. D.A. Kuhn, D. Vanhecke, B. Michen, F. Blank, P. Gehr, A. Petri-Fink, and et al. Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages Beilstein J. Nanotechnol. 5 2014 1625 1636
98. P.H. Hoet, I. Bruske-Hohlfeld, and O.V. Salata Nanoparticles - known and unknown health risks J. Nanobiotechnol. 2 1 2004 12
99. Y. Niwa, Y. Hiura, H. Sawamura, and N. Iwai Inhalation exposure to carbon black induces inflammatory response in rats Circul. J.: Off. J. Jpn. Circ. Soc. 72 1 2008 144 149
100. J.H. Sung, J.H. Ji, J.U. Yoon, D.S. Kim, M.Y. Song, J. Jeong, and et al. Lung function changes in Sprague-Dawley rats after prolonged inhalation exposure to silver nanoparticles Inhalation Toxicol. 20 6 2008 567 574
101. M. Lundborg, R. Bouhafs, P. Gerde, P. Ewing, P. Camner, S.E. Dahlen, and et al. Aggregates of ultrafine particles modulate lipid peroxidation and bacterial killing by alveolar macrophages Environ. Res. 104 2 2007 250 257
102. S. Arora, J. Jain, J.M. Rajwade, and K.M. Paknikar Cellular responses induced by silver nanoparticles: in vitro studies Toxicol. Lett. 179 2 2008 93 100
103. H.W. Taeusch, J. Bernardino de la Serna, J. Perez-Gil, C. Alonso, and J.A. Zasadzinski Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: experimental Biophys. J. 89 3 2005 1769 1779
104. S.A. Shelley Oxidant-induced alterations of lung surfactant system J. Florida Med. Assoc. 81 1 1994 49 51
105. X. Lin, T. Bai, Y.Y. Zuo, and N. Gu Promote potential applications of nanoparticles as respiratory drug carrier: insights from molecular dynamics simulations Nanoscale 6 5 2014 2759 2767
106. G. Hu, B. Jiao, X. Shi, R.P. Valle, Q. Fan, and Y.Y. Zuo Physicochemical properties of nanoparticles regulate translocation across pulmonary surfactant monolayer and formation of lipoprotein corona ACS Nano 7 12 2013 10525 10533
107. Q. Fan, Y.E. Wang, X. Zhao, J.S. Loo, and Y.Y. Zuo Adverse biophysical effects of hydroxyapatite nanoparticles on natural pulmonary surfactant ACS Nano 5 8 2011 6410 6416
108. A.T. Kodama, C.C. Kuo, T. Boatwright, and M. Dennin Investigating the effect of particle size on pulmonary surfactant phase behavior Biophys. J. 107 7 2014 1573 1581
109. C. Schleh, C. Muhlfeld, K. Pulskamp, A. Schmiedl, M. Nassimi, H.D. Lauenstein, and et al. The effect of titanium dioxide nanoparticles on pulmonary surfactant function and ultrastructure Respir. Res. 10 2009 90
110. M.S. Bakshi, L. Zhao, R. Smith, F. Possmayer, and N.O. Petersen Metal nanoparticle pollutants interfere with pulmonary surfactant function in vitro Biophys. J. 94 3 2008 855 868
111. C.A. Ruge, J. Kirch, O. Cañadas, M. Schneider, J. Perez-Gil, U.F. Schaefer, and et al. Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A Nanomed. Nanotechnol. Biol. Med. 7 6 2011 690 693
112. M. Beck-Broichsitter, C. Ruppert, T. Schmehl, A. Guenther, T. Betz, U. Bakowsky, and et al. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro Nanomed. Nanotechnol. Biol. Med. 7 3 2011 341 350
113. M. Beck-Broichsitter, C. Ruppert, T. Schmehl, A. Gunther, and W. Seeger Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles Biochim. Biophys. Acta 1838 1 Pt B 2014 474 481